AdaptHealthAHCO
Recorded

AdaptHealth 2026 UBS Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration36 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Kevin CaliendoHealthcare IT and Distribution Analyst

Good afternoon, everybody. Welcome day two, UBS Global Healthcare Conference. I am Kevin Caliendo, UBS Healthcare IT and Distribution Analyst, and we are very proud and happy today to have with us management team from AdaptHealth, and featuring Suzanne Foster, the CEO. Suzanne, thank you so much for joining us again this year. Maybe before we start, you want to give a quick sort of overview of the last quarter or anything else you want to talk about?

Suzanne FosterCEO

Where we are at as a company?

Kevin CaliendoHealthcare IT and Distribution Analyst

Where you are at as a company.

Suzanne FosterCEO

Where we are today is coming out of, I think, a transformational last year, really. It was about a year ago that we announced that we were taking on a large capitated agreement with Kaiser Permanente. Happy about that, winning that RFP, and that set us on quite an adventure. As I sit here now, being we went live essentially in February, we have learned a lot. There was a lot going into the agreement that we did not anticipate, but we have been able to prove ourselves, and we will get into it in a minute, but we are working with our partner to make sure that it is a financially viable contract and good not only for their members, but for Adapt. That has been the high, the headline of our company. Underlying that, we are coming out of two years of pruning our portfolio.

Suzanne FosterCEO

To remind anyone who is new to this story, we were a company that was a roll-up consolidator of about 150 small HME/DME companies. A couple years ago, we set out to prune parts of the portfolio that came in through all of those acquisitions so that we could become a focused sleep and respiratory business with a supportive, what we call Wellness at Home supplies business. That work is essentially done with the completion of us selling our diabetes segment to Cardinal Health, which will happen in the first half of 2027. We are excited about getting that behind us. The last thing I would say is we have just been on this two-year journey of real operational improvement.

Suzanne FosterCEO

As you can imagine, as a roll-up, we had a lot of disparity around the way we operated, and so these last couple years has been around standard work, bringing discipline and precision to kind of that service element of what we do.

Kevin CaliendoHealthcare IT and Distribution Analyst

Got it. Let us start with Kaiser. It has been the overriding until the ResMed stuff, but the Kaiser contract, you saw a real turnaround in the third quarter after some hiccups and delays. Some things not your fault, for sure. We understand as we have learned. But you moved in the third quarter from negative margins to positive margins. Maybe talk through a little bit, I think it was roughly 10% margin. Is that what you quoted us?

Suzanne FosterCEO

Ended the quarter. Ended the quarter.

Suzanne FosterCEO

With a 14% run rate, yeah.

Kevin CaliendoHealthcare IT and Distribution Analyst

Exiting September at 14% rate. You have reiterated a 20% margin target by late 2027. Maybe take us through what happened, what flipped, and what are the steps that you need to get to to hit your targets? What needs to happen? Sure.

Suzanne FosterCEO

Just real quickly on what happened. So, a fixed fee or capitated agreement in our industry, there is two essential requirements when you enter into those. One is good claims data, so you know exactly the utilization, and the second is the environment in which the referral comes over. Going up until the eve of taking over that business from an incumbent who had it for 21 years, the partnership, I think both Adapt and Kaiser thought we had our arms around that. As it turned out, there were some fundamental flaws, not only in the utilization data, but also in the workflows of how referrals come over. Those are two buckets. When we now, with the benefit of hindsight and seeing the data from when this first initiated in 2023 to go live in 2026, we had some gaps in the data that we didn't see when I last reported in Q2.

Suzanne FosterCEO

Through the partnership, we now see all that data, and there were two things that happened. The first thing was that there was greater than expected utilization increase from the time we bid it to the time we went live, and that's what we're working on adjusting to get the right jump-off point.

Suzanne FosterCEO

Okay. There was also what we saw a little bit, and we've talked about this, that pent-up demand, decreased utilization a few quarters from before we took over the contract that landed on us in the first four months that we took the contract on.

Suzanne FosterCEO

Service had been compressed. We sent out letters to 12 million patients and said, "We're here. We're your new provider," and we got a lot of response. We didn't expect that. That is behind us. So, what you saw in the improvements, the financial improvements, was one, that bolus of utilization is behind us. We're renegotiating on the jump-off point, what it should be from the increased utilization from the time we bid to the time we went live. And on the cost to serve, I call it, the part around the environment, we have, through the partnership, made a lot of improvements.

Suzanne FosterCEO

We've reduced urgent orders. We've worked on what we call the cleanliness of the order, how complete it is. So, through that partnership, we've made a lot of improvements that allowed us to really get after in Q3 the labor and the OpEx, and that's how we were able to turn those margins from negative 4% to now run rating in September at 14%. It was mostly labor and OpEx that drove that. The relationship is very stable. We're in active negotiations to right-size the financial profile ahead of schedule of what we promised to the street when we didn't have all this information.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day